|
DrugPatentWatch concentrates deep knowledge on more than 6,400 small-molecule drugs and 2,300 generic ingredients from 1,700 branded and generic pharmaceutical companies and 700 suppliers, and more than 4,300 active and expired US patents and 74,000 international patents spanning 93 countries and regional patent offices. |
Generic Name: silodosin
Clinical Trials for: silodosinUse of Silodosin to Treat Moderate to Severe Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome. Status: Completed Condition: Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome Effectiveness and Safety of Silodosin in the Treatment of Benign Prostatic Hyperplasia Status: Active, not recruiting Condition: Benign Prostatic Hyperplasia Safety and Efficacy of QD Versus BID Silodosin With Lower Urinary Tract Symptoms Suggestive of BPH Status: Completed Condition: Benign Prostatic Hypertrophy Study of a α1A Adrenoceptor Selective Antagonist Silodosin to Treat Severe Benign Prostatic Hyperplasia(BPH) Status: Completed Condition: Benign Prostatic Hyperplasia Efficacy and Safety of Silodosin on Voiding Dysfunction Associated With Neurogenic Bladder Status: Completed Condition: Neurogenic Bladder; Voiding Dysfunction A Study of Silodosin 8 mg Daily for the Treatment of Nocturia in Men With Benign Prostatic Hyperplasia Status: Completed Condition: Nocturia; Prostatic Hyperplasia A Dose-finding Study of Silodosin in Patients With Urinary Calculi Status: Recruiting Condition: Urinary Calculus Differential Effect of Silodosin Versus Tamsulosin on Stone Clearance After Extra-corporeal Shock Wave Lithotripsy Status: Not yet recruiting Condition: Kidney Stones Efficacy and Safety of Silodosin in the Treatment of Natural Expulsion in Patients With Ureteral Stones Status: Enrolling by invitation Condition: Ureteral Stone Evaluation of the Efficacy and Safety of Silodosin in the Treatment of the Signs and Symptoms of BPH Status: Completed Condition: Benign Prostatic Hyperplasia Courtesy of ClinicalTrials.org See more clinical trials for this drug | |
Glossary
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist_Flag | Patent Expiration | Patented / Exclusive Use | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Watson Labs | RAPAFLO | silodosin | CAPSULE; ORAL | 022206 | Oct 8, 2008 | RX | No | <disabled> | NEW CHEMICAL ENTITY | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Watson Labs | RAPAFLO | silodosin | CAPSULE; ORAL | 022206 | Oct 8, 2008 | RX | No | 5,780,485 | <disabled> | USE IN THE TREATMENT OF THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Watson Labs | RAPAFLO | silodosin | CAPSULE; ORAL | 022206 | Oct 8, 2008 | RX | No | 5,403,847 | <disabled> | USE IN THE TREATMENT OF THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Watson Labs | RAPAFLO | silodosin | CAPSULE; ORAL | 022206 | Oct 8, 2008 | RX | No | 5,387,603 | Y | Y | <disabled> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| The preview shows a limited data set. Complete access is available with a Subscription | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
« Back to Dashboard
DrugPatentWatch Archives
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Connect with Social Media:
Copyright © 2002-2013 thinkBiotech LLC. ISSN: 2162-2639
`abc